Does uterine cancer show up in blood work? Not through any routine blood test. A complete blood count or metabolic panel cannot detect or exclude uterine cancer, and no blood test is approved to screen for it. Blood work can reveal anemia, support staging, and track treatment response. Diagnosis still requires tissue from the uterus.

That answer holds across tumor types and stages. The rest of this explainer covers why blood work falls short, which secondary signals do appear, what the numbers mean, and where clinicians draw the line between supportive testing and actual diagnosis.

Why blood can't carry a definitive uterine cancer signal

Uterine cancer begins as a clonal overgrowth of cells lining the endometrium, the inner cavity of the uterus. A tumor must grow large enough and invade deeply enough to shed cells or proteins into the bloodstream. Early-stage disease usually stays confined, so the blood compartment often carries nothing distinctive.

Circulating tumor cells are rare even in advanced disease. A milliliter of blood contains billions of red cells and millions of white cells; shed tumor cells number in the single digits at best. Detection platforms must find a handful of abnormal cells among a vast normal background.

Common blood markers lack the specificity to serve as a screening tool. CA-125 is a protein on the surface of some ovarian and endometrial cells. It rises in endometriosis, pelvic infection, pregnancy, liver disease, and menstruation. A marker that flags many benign conditions cannot cleanly identify one cancer.

The clinical consequence is straightforward. A normal blood panel never rules out uterine cancer, and an abnormal one never confirms it. Tissue diagnosis remains the anchor.

What routine blood work actually reveals

Routine panels contribute indirect evidence rather than a direct cancer signal. Abnormal uterine bleeding is the most common presenting symptom, and chronic blood loss depletes iron stores before hemoglobin falls. A complete blood count may show microcytic anemia: low hemoglobin with small, pale red cells.

Inflammation markers can shift. platelets may rise (thrombocytosis) as part of a systemic inflammatory response. The neutrophil-to-lymphocyte ratio has drawn research interest as a prognostic signal, though it cannot diagnose cancer. These are associations across populations, not individual tests.

A basic metabolic panel matters mainly before treatment. It establishes kidney function, electrolytes, and liver enzymes so surgery and systemic therapy can proceed safely. None of these values distinguishes a malignant from a benign uterus.

The counterintuitive detail: a completely normal blood count is common in early uterine cancer. Women diagnosed at stage I often have entirely unremarkable labs. Reassuring blood work should never be read as reassurance against cancer.

Quantified context: markers, ranges, and limits

CA-125 is the most studied serum marker linked to uterine cancer. It is elevated in a minority of early-stage cases and more often in advanced or high-grade disease. The commonly cited reference cutoff is 35 units per milliliter, but values below it occur in confirmed cancer and values above it occur in benign conditions.

The overlap is the problem. Endometriosis alone can push CA-125 into the hundreds. Cirrhosis, pelvic inflammatory disease, and even early pregnancy raise it. Sensitivity and specificity depend heavily on the population tested and the stage distribution.

Human epididymis protein 4 (HE4) has been evaluated alongside CA-125. It is less affected by endometriosis, which improves specificity in some settings. Neither marker is validated for population screening of uterine cancer.

HE4 requires careful interpretation in kidney impairment, because renal clearance alters serum levels. That dependency limits its use in patients with reduced kidney function.

No serum test has received FDA approval as a screening tool for endometrial cancer. Guideline bodies recommend diagnosis by endometrial sampling, not by blood marker. This is a stable regulatory position rather than a dated one.

Comparison: what each test can and cannot do

Test Primary purpose Can it diagnose uterine cancer? Key limitation
Complete blood count Detect anemia, infection, platelet change No Normal results are common in early disease
Basic metabolic panel Baseline kidney and liver function No No cancer-specific signal
CA-125 Monitor or support evaluation No Rises in many benign conditions
HE4 Supportive marker, often with CA-125 No Altered by kidney function
Circulating tumor DNA (ctDNA) Research and some monitoring roles No, not for diagnosis Low sensitivity in early or low-volume disease
Endometrial biopsy Tissue diagnosis Yes, this is the diagnostic standard Requires sampling the uterus directly

The table makes the hierarchy explicit. Blood tests occupy supportive roles. Only tissue sampling reaches diagnostic certainty.

The diagnostic pathway and where blood work fits

Symptoms usually drive the workup. Postmenopausal bleeding is the classic red flag, and any bleeding after menopause warrants evaluation regardless of blood results. Premenopausal patients may present with heavy or intermenstrual bleeding that persists.

Transvaginal ultrasound measures endometrial thickness. In a postmenopausal woman, a thin, uniform endometrium lowers the probability of cancer, though no single cutoff eliminates it. Thickening or heterogeneity prompts sampling.

Endometrial biopsy is the decisive step. Office pipelle sampling can establish diagnosis without anesthesia in many cases. Hysteroscopy with directed biopsy is used when sampling is inadequate or lesions are focal.

Blood work runs alongside this pathway. It identifies anemia needing correction before surgery, flags comorbidities, and provides baseline values for staging. It never substitutes for the biopsy.

Timeline: from symptom to staging

Stage Typical interval What happens Role of blood work
Symptom onset Day 0 Postmenopausal or abnormal bleeding noted None
Initial evaluation Within weeks Pelvic exam, transvaginal ultrasound CBC to assess anemia
Tissue sampling After imaging Endometrial biopsy or hysteroscopy Pre-procedure baseline labs
Diagnosis Days after biopsy Pathology confirms histology and grade Metabolic panel before treatment
Staging Preoperative Imaging for extent of disease CBC, metabolic panel, sometimes CA-125
Treatment Weeks after staging Surgery, and systemic therapy if indicated Monitoring counts and organ function
Surveillance Years Scheduled exams and imaging Blood work as clinically indicated

Intervals are approximate and vary with health-system access and clinical urgency. No fixed calendar exists.

Red flags that override blood results

Any vaginal bleeding after menopause, regardless of lab values New or persistent abnormal bleeding between periods or after intercourse Postmenopausal discharge that is watery, blood-tinged, or new Pelvic pain or pressure with a new bowel or bladder habit Unexplained iron-deficiency anemia, especially in a postmenopausal woman A pelvic mass or thickened endometrium on imaging

Each bullet reflects a symptom pattern that warrants prompt evaluation. None can be cleared by a normal blood panel. The last two are where blood work and imaging converge: anemia may prompt a search for a bleeding source, and imaging may find an incidental finding.

Misconceptions about blood tests and uterine cancer

The first misconception is that a normal CBC means no cancer. It does not. Early endometrial cancer frequently produces no hematologic change at all.

The second is that CA-125 functions as a screening test. It does not. It is a supportive and monitoring tool with limited specificity, and it is not approved for population screening of uterine cancer.

The third is that a "tumor marker panel" offers a comprehensive answer. Multiplex panels can generate incidental elevations that trigger anxiety and further testing without improving diagnosis. A single elevated value in a low-risk patient is often noise.

The fourth is that blood tests can replace biopsy. No serum test has the accuracy to substitute for endometrial tissue sampling. The tissue is the issue.

The fifth is that a rising marker during surveillance always means recurrence. Benign inflammation and other conditions can mimic progression, so trends are interpreted with imaging and examination rather than in isolation.

What you can do with this information

Treat bleeding patterns as the primary signal. Track the timing, duration, and volume of any abnormal bleeding and report it. Postmenopausal bleeding should prompt a call within days, not months.

Ask for the right test. If bleeding is abnormal, ask whether transvaginal ultrasound and endometrial biopsy are indicated. Blood work alone will not answer the question.

Use blood work for what it does well. Correct anemia before surgery if your clinician recommends it. Complete baseline panels so treatment planning is not delayed.

Interpret markers in context. If CA-125 is ordered, discuss what the number means for your situation rather than comparing it to someone else's. A single value rarely changes management on its own.

Keep surveillance organized. If you are in follow-up after treatment, confirm the schedule for exams, imaging, and any labs. Missing appointments is a bigger risk than any single blood value.

Limits of what blood work can tell you

Blood work cannot confirm or exclude uterine cancer, cannot determine stage on its own, and cannot substitute for tissue diagnosis. Its value is indirect: detecting anemia, establishing baseline organ function, and supporting treatment decisions.

Research on ctDNA and multi-analyte panels continues. Any future screening test would need to prove sensitivity and specificity in large populations before replacing or supplementing current pathways. Until then, symptoms and tissue sampling remain the diagnostic backbone, and blood tests remain supporting players.

If you have unexplained bleeding or a new pelvic symptom, the next step is a clinical evaluation, not another lab draw.